Hai-Rangsubbs Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2019
About Hai-Rangsubbs Pharma
Hai-Rangsubbs Pharma Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 August 2018 (Six years and five months 28 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
David Mizrahi and Srinivas Boyalapalli serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299TG2018PTC126364
- Company No.
126364
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Aug 2018
- Date of AGM
30 Dec 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Hai-Rangsubbs Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
David Mizrahi  | Director | 30-Aug-2018 | Current |
Srinivas Boyalapalli  | Director | 30-Aug-2018 | Current |
Financial Performance of Hai-Rangsubbs Pharma.
Hai-Rangsubbs Pharma Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Hai-Rangsubbs Pharma?
Unlock access to Hai-Rangsubbs Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Rangsubbs Pharmaceuticals (India) Private LimitedSrinivas Boyalapalli is a mutual person
M.D.Pomegranate Plantation India Private LimitedDavid Mizrahi is a mutual person
- Mizrahi Agtech Private Limited
David Mizrahi is a mutual person
- Vikda India Private Limited
David Mizrahi is a mutual person
- Indira Ravi Healthcare India Private Limited
Srinivas Boyalapalli is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hai-Rangsubbs Pharma?
Unlock and access historical data on people associated with Hai-Rangsubbs Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hai-Rangsubbs Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hai-Rangsubbs Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.